Radiopharm Theranostics (RADX) Income Statement: Revenue & Earnings

Radiopharm Theranostics Income Statement Analysis

Revenue, earnings, and profit margins in millions AUD

Scale:

Scroll to see more

Radiopharm Theranostics Limited income statement - Annual data in millions AUD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 2025	Dec 2024	Jun 2023	Jun 2022	Jun 2021
Revenue & Gross Profit
Revenue	3.63	3.63	0.29	0.01	0.00
Cost of Revenue	3.59	3.59	19.53	7.49	0.00
Gross Profit	0.04	0.04	0.29	-7.49	0.00
Operating Expenses
Research & Development	27.52	27.52	22.63	4.12	0.00
Selling, General & Administrative	16.53	16.53	15.26	7.64	0.30
Operating Expenses	34.68	38.21	31.98	12.44	1.16
Operating Income	-34.64	-38.17	-31.69	-19.93	-1.16
Other Income/Expense
Interest Income	0.89	0.89	0.15	0.01	0.00
Interest Expense	0.07	0.07	0.09	-9.35	0.00
Other Income/Expense	-3.93	-0.07	-2.94	-1.03	0.00
Income
Income Before Tax	-38.24	-38.24	-34.57	-30.38	-1.16
Income Tax Expense	0.10	0.10	0.04	0.04	0.00
Net Income	-38.34	-38.34	-34.61	-30.42	-1.16
Net Income - Continuous Operations	-38.34	-38.34	-34.61	-30.34	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-38.17	-38.17	-34.48	-16.94	0.00
EBIT	-38.17	-35.33	-34.49	-19.93	-1.16
Depreciation & Amortization	0.01	0.01	0.01	2.98	0.00
Earnings Per Share
Basic EPS	-5.00	-5.00	-32.00	-	-
Diluted EPS	-5.00	-5.00	-32.00	-	-
Basic Shares Outstanding	6.94	6.94	1.08	181.25	0.00
Diluted Shares Outstanding	6.95	6.94	1.08	181.25	0.00